# NAVIDEA BIOPHARMACEUTICALS, INC.

NAVIDEA BIOPHARMACEUTICALS, INC. is a company headquartered in Dublin, OH, United States.

## Company overview

- **Legal name:** NAVIDEA BIOPHARMACEUTICALS, INC.
- **Former names in filing history:** NEOPROBE CORP (1995-02-10 to 2011-12-30)
- **Classification:** Company
- **Industry (SIC):** 2835 — In Vitro & In Vivo Diagnostic Substances
- **Headquarters:** Dublin, OH, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000810509

## About

NAVIDEA BIOPHARMACEUTICALS, INC. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000810509, and its reported industry is In Vitro & In Vivo Diagnostic Substances. In 10-K filed on 2023-03-27, it reported annual revenue of USD 65,652; net income of USD -15,177,153; total assets of USD 4,371,606 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $65,652 (USD 65,652)
- **Net income:** -$15.2M (USD -15,177,153)
- **Total assets:** $4.4M (USD 4,371,606)
- **Cash and equivalents:** $2.0M (USD 1,995,860)
- **Operating cash flow:** -$9.0M (USD -8,986,570)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $531,513 (USD 531,513)
- **Total assets:** $6.6M (USD 6,644,833)
- **Cash and equivalents:** $4.2M (USD 4,230,865)
- **Operating cash flow:** -$10.2M (USD -10,218,155)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $915,013 (USD 915,013)
- **Total assets:** $7.8M (USD 7,758,018)
- **Cash and equivalents:** $2.7M (USD 2,670,495)
- **Operating cash flow:** -$8.2M (USD -8,173,793)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $657,826 (USD 657,826)
- **Total assets:** $4.2M (USD 4,150,906)
- **Cash and equivalents:** $1.0M (USD 1,047,159)
- **Operating cash flow:** -$9.4M (USD -9,354,730)

## Recent SEC filings

- Form 8-K — filed 2023-12-01 — period 2023-11-27 — FORM 8-K
- Form 8-K — filed 2023-11-16 — period 2023-11-10 — FORM 8-K
- Form 10-Q — filed 2023-11-14 — period 2023-09-30 — FORM 10-Q
- Form DEF 14A — filed 2023-10-05 — period 2023-11-16 — FORM DEF 14A
- Form 10-Q — filed 2023-08-11 — period 2023-06-30 — FORM 10-Q
- Form 8-K — filed 2023-08-08 — period 2023-08-03 — FORM 8-K
- Form 8-K — filed 2023-07-28 — period 2023-07-24 — FORM 8-K
- Form 8-K — filed 2023-07-13 — period 2023-07-11 — FORM 8-K
- Form 8-K — filed 2023-07-06 — period 2023-06-29 — FORM 8-K
- Form DEF 14A — filed 2023-07-03 — period 2023-07-27 — FORM DEF 14A
- Form 8-K — filed 2023-06-16 — period 2023-06-14 — FORM 8-K
- Form 8-K — filed 2023-06-16 — period 2023-06-16 — FORM 8-K

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/navidea-biopharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology